Triaminic Allerchews
This article was originally published in The Tan Sheet
Executive Summary
Upcoming late January launch of 10 mg loratadine quick-dissolve, wintergreen-flavored tablets under Triaminic children's cough/cold line may provide Novartis Consumer Healthcare's OTC unit with a strong start to 2004 sales. Triaminic Allerchews will debut in 8- and 24-count packages with substantial consumer and trade promotion support, Novartis says. The product will compete against Schering-Plough's Claritin Children's Formula Syrup, which contains 5 mg loratadine per dose (1"The Tan Sheet" July 28, 2003, p. 11)...
You may also be interested in...
Novartis CEO Calls Potential Schering-Plough Merger “Very Interesting”
A Novartis/Schering-Plough merger would increase Novartis' OTC portfolio by about 57% to $2.77 bil. and give the Swiss firm control over the formidable Claritin allergy and hives relief franchise
Novartis OTC Business Makes Net Gains On Loratadine Sales In Q2
Novartis Consumer Healthcare's OTC unit is looking to its loratadine products to continue improving the division's net earnings for the remainder of the year
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”